Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims

1. (Original) A compound of the Formula Ia:



Ia

or a pharmaceutically acceptable salt or solvate thereof

wherein,

L- is a Ligand unit;

-A- is a Stretcher unit;

a is 0 or 1;

each -W- is independently an Amino Acid unit;

-Y- is a Spacer unit;

w is an integer ranging from 0 to 12;

y is 0, 1 or 2;

p ranges from 1 to about 20; and

-D is a Drug unit of the formula



wherein, independently at each location:

R^2 is selected from -H and -C_1-C_8 alkyl;

R^3 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

R^4 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8

heterocycle) wherein R^5 is selected from -H and -methyl; or R^4 and R^5 join, have the formula $-(CR^aR^b)_n-$ wherein R^a and R^b are independently selected from -H, $-C_1$-C_8 alkyl and $-C_3$-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and $-C_1$-C_8 alkyl;

R^7 is selected from -H, $-C_1$-C_8 alkyl, $-C_3$-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, $-C_1$-C_8 alkyl-aryl, $-C_1$-C_8 alkyl-(C_3-C_8 carbocycle), $-C_3$-C_8 heterocycle and $-C_1$-C_8 alkyl-(C_3-C_8 heterocycle);

each R^8 is independently selected from -H, -OH, $-C_1$-C_8 alkyl, $-C_3$-C_8 carbocycle and -O-(C_1-C_8 alkyl);

R^9 is selected from -H and $-C_1$-C_8 alkyl;

R^{10} is selected from



,


and


;

Z is -O-, -S-, -NH- or $-N(R^{14})-$;

R^{11} is selected from -H, -OH, $-NH_2$, $-NHR^{14}$, $-N(R^{14})_2$, $-C_1$-C_8 alkyl, $-C_3$-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, $-C_1$-C_8 alkyl-aryl, $-C_1$-C_8 alkyl-(C_3-C_8 carbocycle), $-C_3$-C_8 heterocycle and $-C_1$-C_8 alkyl-(C_3-C_8 heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

each R^{12} is independently selected from -aryl and $-C_3$-C_8 heterocycle;

R^{13} is selected from -H, -OH, $-NH_2$, $-NHR^{14}$, $-N(R^{14})_2$, $-C_1$-C_8 alkyl, $-C_3$-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, $-C_1$-C_8 alkyl-aryl, $-C_1$-C_8 alkyl-(C_3-C_8 carbocycle), C_3-C_8 heterocycle and $-C_1$-$_8$ alkyl-(C_3-C_8 heterocycle); and

Each R^{14} is independently -H or $-C_1$-C_8 alkyl.

2. (Original) The compound of claim 1 wherein w is an integer ranging from 2 to 12.

3-6. (Canceled)

7. (Original) A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -D is a Drug unit having the structure



or a pharmaceutically acceptable salt or solvate thereof,

wherein, independently at each location:

R^2 is selected from -H and -methyl;

R^3 is selected from -H, -methyl, and -isopropyl;

R^4 is selected from -H and -methyl; R^5 is selected from -isopropyl, -isobutyl, -sec-butyl, -methyl and -t-butyl or R^4 and R^5 join, have the formula $-(CR^aR^b)_n-$ where R^a and R^b are independently selected from -H, -C_1-C_8 alkyl, and -C_3-C_8 carbocycle, and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -methyl;

each R^8 is independently selected from -OH, -methoxy and -ethoxy;

R^{10} is selected from



and

;

R^{24} is selected from H and -C(O)R^{25}-; wherein R^{25} is selected from -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

Z is -O-, -NH-, -OC(O)-, -NHC(O)-, -NR^{28}C(O)- ; where R^{28} is selected from -H and -C_1-C_8 alkyl;

n is 0 or 1; and

R^{27} is selected from -H, $-N_3$, $-C_1$-C_8 alkyl, $-C_3$-C_8 carbocycle, -aryl, $-C_1$-C_8 alkyl-aryl, $-C_1$-C_8 alkyl-(C_3-C_8 carbocycle), $-C_3$-C_8 heterocycle and $-C_1$-C_8 alkyl-(C_3-C_8 heterocycle) when n is 0; and R^{27} is selected from -H, $-C_1$-C_8 alkyl, $-C_3$-C_8 carbocycle, -aryl, $-C_1$-C_8 alkyl-aryl, $-C_1$-C_8 alkyl-(C_3-C_8 carbocycle), $-C_3$-C_8 heterocycle and $-C_1$-C_8 alkyl-(C_3-C_8 heterocycle) when n is 1.

8. (Canceled)

9. (Original) A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -D is a Drug unit having the structure



10-16. (Canceled)

17. (Previously Presented) A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where the Ligand unit is an antibody unit.

18. (Original) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 17 where the antibody unit is a monoclonal antibody unit.

19. (Original) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 18 where the monoclonal antibody unit is cBR96, cAC10 or 1F6.

20. (Previously Presented) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where $-Y_y-$ is



Q is selected from -C_1-C_8 alkyl, -O-(C_1-C_8 alkyl), -halogen, -nitro and -cyano; and m is an integer ranging from 0-4, the amino terminus of -Y_y- forming a bond with a Amino acid unit and the carboxyl terminus of -Y_y- forming a bond with an Drug unit.

21. (Previously Presented) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -A- is



and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.

22. (Previously Presented) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -A- is



and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.

23. (Previously Presented) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -A- is



and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.

24. (Previously Presented) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -A- is



and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.

25. (Previously Presented) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -A- is



and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.

26. (Previously Presented) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -A- is



the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.

27. (Original) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 21 where -A- is



the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.

28. (Original) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 22 where -A- is



the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.

29. (Original) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 24 where -A- is



the carbonyl terminus of -A- forming a bond with an Amino Acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.

30. (Previously Presented) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -W_w- is -Phenylalanine-Lysine- or-valine-citrulline-, the amino terminus of -W_w- forming a bond with a Stretcher unit when a is 1 or with a Ligand unit if a is 0, and the C- terminus of -W_w- forming a bond with a Spacer unit when y is 1 or 2, and with a Drug unit when y is 0.

31-43. (Canceled)

44. (Previously Presented) A compound of the formula



or a pharmaceutically acceptable salt or solvate thereof

wherein, independently at each location:

R^2 is selected from -H and -C_1-C_8 alkyl;

R^3 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

R^4 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle) wherein R^5 is selected from -H and -methyl; or R^4 and R^5 join, have the formula -$(CR^aR^b)_n$- wherein R^a and R^b are independently selected from -H, -C_1-C_8 alkyl and -C_3-C_8 carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -C_1-C_8 alkyl;

R^7 is selected from -H, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle);

each R^8 is independently selected from -H, -OH, -C_1-C_8 alkyl, -C_3-C_8 carbocycle and -O-(C_1-C_8 alkoxy);

R^9 is selected from -H and -C_1-C_8 alkyl;

R^{11} is selected from -H, -OH, -NH_2, -NHR^{14}, -$N(R^{14})_2$, -C_1-C_8 alkyl, -C_3-C_8 carbocycle, -O-(C_1-C_8 alkyl), -aryl, -C_1-C_8 alkyl-aryl, -C_1-C_8 alkyl-(C_3-C_8 carbocycle), -C_3-C_8 heterocycle and -C_1-C_8 alkyl-(C_3-C_8 heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

each R^{12} is independently selected from -aryl and -C_3-C_8 heterocycle;

R^{13} is selected from -H, -OH, $-NH_2$, $-NHR^{14}$, $-N(R^{14})_2$, $-C_1$-C_8 alkyl, $-C_3$-C_8 carbocycle, -O-(C_1-C_8 alkoxy), -aryl, $-C_1$-C_8 alkyl-aryl, $-C_1$-C_8 alkyl-(C_3-C_8 carbocycle), $-C_3$-C_8 heterocycle and $-C_1$-C_8 alkyl-(C_3-C_8 heterocycle);

each R^{14} is independently -H or $-C_1$-C_8 alkyl;

R^{16} is A'_a-W_w-Y_y-

wherein

each -W- is independently an Amino Acid unit;

-Y- is a Spacer unit;

w is an integer ranging from 0 to 12;

y is 0, 1 or 2; and

-A' is selected from


;


;


;


;


;


;


;


; and


;

wherein

G is selected from -Cl, -Br, -I, -O-mesyl and -O-tosyl;

J is selected from -Cl, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR^{18};

a is 0 or 1;

R^{17} is selected from -C_1-C_{10} alkylene-, -C_3-C_8 carbocyclo-, -O-(C_1-C_8 alkoxy)-, -arylene-, -C_1-C_{10} alkylene-arylene-, -arylene-C_1-C_{10} alkylene-, -C_1-C_{10} alkylene-(C_3-C_8 carbocyclo)-, -(C_3-C_8 carbocyclo)-C_1-C_{10} alkylene-, -C_3-C_8 heterocyclo-, -C_1-C_{10} alkylene-(C_3-C_8 heterocyclo)-, -(C_3-C_8 heterocyclo)-C_1-C_{10} alkylene-, -$(CH_2CH_2O)_r$-, and -$(CH_2CH_2O)_r$-CH_2-;

r is an integer ranging from 1-10; and

R^{18} is -C_1-C_8 alkyl or -aryl.

45. (Original) The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

46. (Original) The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

47. (Canceled)

48. (Original) The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

49. (Previously Presented) The compound of claim 44 having the structure


;


; or



or a pharmaceutically acceptable salt or solvate thereof.

50-51. (Canceled)

52. (Original) The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

53. (Canceled)

54. (Original) The compound of claim 1 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

55. (Canceled)

56. (Original) The compound of claim 1 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

57-58. (Canceled)

59. (Original) The compound of claim 1 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

60-62. (Canceled)

63. (Previously Presented) The compound of claim 1 having the structure





p; or



p

where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

64-65. (Canceled)

66. (Previously Presented) The compound of any one of claims 54, 56, 59 or 63 where p ranges from about 7 to about 9, from about 3 to about 5, or about 1 to about 3.

67-76. (Canceled)

77. (Previously Presented) The compound of claim 1 having the formula



p

or a pharmaceutically acceptable salt or solvate thereof,

where p ranges from about 7 to about 9, from about 3 to about 5, or about 1 to about 3,

wherein L is cBR96, cAC10, an anti-CD40 antibody or an anti-CD20 antibody.

78. (Canceled)

79. (Previously Presented) The compound of claim 1 having the formula



or a pharmaceutically acceptable salt or solvate thereof,
where p ranges from about 7 to about 9, from about 3 to about 5, or about 1 to about 3, wherein L is cBR96, cAC10, an anti-CD40 antibody or an anti-CD20 antibody.

80-99. (Canceled)

100. (Previously Presented) The compound of claim 79 wherein L is rituximab.

101. (Canceled)

102. (Previously Presented) The compound of claim 77 or 79 wherein L is S2C6.

103. (Canceled)

104. (Previously Presented) The compound of claim 77 wherein L is rituximab.

105-110. (Canceled)

111. (Currently Amended) A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 1, 44, 77, 79, 99, 100~~, 102~~ or 104 and a pharmaceutically acceptable carrier or vehicle.

112. (Currently Amended) A method for killing or inhibiting the multiplication of a tumor cell or cancer cell comprising administering to an animal in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 1, 44, 77, 79, 99, 100~~, 102~~ or 104.

113. (Currently Amended) A method for treating cancer, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 44, 77, 79, 99, 100~~, 102~~ or 104.

114. (Currently Amended) A method for treating an autoimmune disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 44, 77, 79, 99, 100~~, 102~~ or 104.

115. (Currently Amended) A method for treating an infectious disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 44, 77, 79, 99, 100~~, 102~~ or 104.

116. (Original) The method of claim 113 further comprising administering to the animal an effective amount of an anticancer agent.

117. (Original) The method of claim 114 further comprising administering to the animal an effective amount of an immunosuppressant agent.

118. (Original) The method of claim 115 further comprising administering to the animal an effective amount of an anti-infectious agent.

119. (Currently Amended) The compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 1, 44, 77, 79, 99, 100~~, 102~~ or 104, in an isolated or a purified form.